SZN-043 preclinical data shows rapid, transient increases in hepatocyte proliferation and was well tolerated in non-clinical toxicology studiesSZN-1326 preclinical data...
Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE)...
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent...
FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide Commercial launch planned in Q1 2023...
Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation of PRAME...
Phase 3 Clinical Trial to Proceed to Second Interim Analysis Expected to Occur in 2023SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022...
First Genetically Modified (TALEN®-edited) Iovance TIL Therapy with Inactivated PD-1 Expression SAN CARLOS, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) --...
Poster presentation indicates new microgranule formulation elicited desired delayed release profile, offering protection at acidic pH and rapid release under...
DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing...
Complements Existing Allowance in the U.S. as Global Jurisdictions Recognize the Uniqueness of the TechnologyHINGHAM, Mass., Oct. 10, 2022 (GLOBE...
NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
Saint-Herblain (France), October 10, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it...
HOUSTON and BURLINGTON, Ontario, Oct. 07, 2022 (GLOBE NEWSWIRE) -- RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage biotechnology company announced...
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038...
New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE)...
Integration with the LIBERTY® Robotic System & One & Done™ Technology May Enable Future Acceleration of Robotic Adoption; Represents an...
ZUG, Switzerland, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to...